One of the alternatively spliced transcripts of the leptin receptor lacks of intracellular-transmembrane domain and is a putative soluble leptin receptor (SLR). In the present study, we investigated if the differences of repartition of free and bound leptin between obese and lean patients might be related to their different levels of SLR in plasma. METHODS: Subjects of the GENOLOR study were divided in three group; obese (26 men and 92 women; BMI 30.0 ± 44.1 kgam 2 ); overweight (11 men and 29 women; BMI 25.1 ± 29.9 kgam 2 ) and lean (16 men and 48 women; BMI 17.6 ± 25.0 kgam 2 ). A direct double monoclonal ELISA was developed to measure SLR using a monoclonal antibody and the recombinant human leptin receptor extracellular domain. Leptin measurement was done by RIA (Linco Research Inc). RESULTS: The recombinant SLR was able to bind human leptin with a Kd of 3 nM (by surface plasmon resonance). Our ELISA was speci®c to SLR and demonstrated no interference with leptin concentrations, indicating that it measured total plasma SLR. The intra-assay and inter-assay coef®cient of variations were 2.8% and 8.3%, respectively. In human plasma, SLR levels range from 10.6 to 100.9 ngaml. Leptin levels were more elevated in obese (34.0 AE 16.0 ngaml) than in overweight (20.5 AE 12.8 ngaml) and lean subjects (9.8 AE 8.2 ngaml). Surprisingly, SLR levels were more elevated in lean (51.2 AE 12.5 ngaml) than overweight (40.2 AE 14.9 ngaml) and obese (28.7 AE 8.8 ngaml) subjects (ANOVA; p`0.0001). SLR levels were more elevated in men (46.0 AE 15.2 ngaml) than in women (34.9 AE 13.9 ngaml) but this difference disappeared after adjustment by fat mass. Individual SLR levels were inversely correlated to body weight, BMI, fat mass, percent of fat mass and leptin levels (respectively r 2 0.33; r 2 0.49; r 2 0.58; r 2 0.57; r 2 0.56; p`0.0001). CONCLUSION: The soluble leptin receptor is present in human plasma where it binds leptin. Its level is inversely related to the degree of obesity, indicating a possible role in modulating the effect of leptin on body weight. The low level observed in obese patients could not be responsible for a decrease in plasma free leptin. Inversely, a possible role of the soluble leptin receptor would be to maintain an active pool of bound leptin protected from metabolic clearance mechanisms.
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O69
Mesenchymal stem cells ± a new model for the study of the early stages of human adipogenesis RESULTS: Under these experimental conditions, cells started to accumulate lipids after the ®rst cycle of hormonal induction, but the most pronounced change in the phenotype was observed during the third cycle of induction (morphological observation). After 21 days of differentiation, approximately 20% ± 40% of the cells were fully differentiated into adipocytes. Data from RT-PCR suggest an early start of adipogenesis after the ®rst hormonal induction, i.e. mRNA levels of PPARg increased after 12 hours of induction, while elevation of adipsin mRNA levels was delayed about 1.5 days compared to PPARg. A late marker of differentiation, aP2, was detected only after the third cycle of induction. Increased levels of PCNA mRNA during the ®rst 12 hours of differentiation suggest that cells undergo mitosis prior to differentiation. Protein levels of CaEBPb (LAP form) and GLUT1 varied after each cycle of hormonal induction, i.e. increased after induction and then slightly decreased before the next cycle of induction. The LIP form of CaEBPb followed the opposite pattern of expression compared to LAP form. We also examined protein levels of b 3 adrenoreceptor (AR) that is only weakly expressed in mature human white adipocytes. b 3 AR protein transiently increased after hormonal induction but then the levels decreased thereafter. CONCLUSION: These results suggest that hMSC may provide a valid model for studying the recruitment of human preadipocytes from these precursors.
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Insulin increases inducible nitric oxide synthase (iNOS) activity in adipocytes 
INTRODUCTION:
We have previously shown that both endotoxemia and obesity are associated with increased expression of the inducible form of nitric oxide synthase (iNOS) in skeletal muscle and adipose tissues. Moreover, chronic treatment of cultured skeletal muscle and adipose cells with proin¯ammatory cytokines and the endotoxin LPS can enhance the expression of iNOS and the production of high nitric oxide (NO) concentrations. The hormonal regulation of iNOS expression and activity is not well known.
We have previously observed that insulin inhibits iNOS activity by a posttranscriptionnal mechanism (Diahelologia,1998;41:1523 ± 7). The main goal of the present study was to investigate the effect of insulin on iNOS expressionlactivity in brown and white adipocytes. METHODS: Cell lines of brown (T37i) and white (3T3-L1) adipocytes as well as adipose explants (2 ± 3 mg, isolated from fat pads of normal rats) were incubated or not with cytokines (TNF-a, IFN-g) and LPS for 24 hrs. Parallel experiments were performed in the presence of insulin. NO production was evaluated by NO 2 accumulation in medium as measured by the Griess assay. iNOS mRNA and protein levels were assessed by RT-PCR and Western blot analyses, respectively. iNOS enzymatic activity was measured by the conversion of 3 H L-arginine to 3 H L-citrulline in the presence or not of the speci®c iNOS inhibitor 1400 W. RESULTS: In contrast to skeletal myocytes, insulin was found to potentiate the effects of cytokinesaLPS on NO production by up to 30%. Experiments with individual cytokines or LPS further showed that insulin potentiated the cytokinesaLPS response mainly by increasing the effect of TNF-a (3-fold increase with insulin exposure). The effect of insulin on cytokine-mediated NO production could not be explained by an increase iNOS gene transcription or traduction since neither iNOS mRNA nor iNOS protein levels were altered by the hormone. However, insulin directly enhanced iNOS activity as demonstrated by measurements of 3 H L-citrulline formation in cell extracts from insulin-treated cells or during exposure of living adipose cells to insulin. CONCLUSION: Insulin increases the stimulatory effects of cytokinesaLPS on iNOS-dependent NO formation in both white and brown adipocytes. Our data further indicate that this effect can be explained by a direct action of insulin on iNOS enzymatic activity. Thus, insulin may contribute to the increased iNOS-mediated NO production in adipose cells during endotoxemia and obesity. 
The principal goal of the present study was to analyze the nature of the b-adrenergic pathways regulating insulin-stimulation of leptin secretion from isolated rat adipocytes. METHODS: Adipocytes were isolated from rat (Wistar) epididymal white adipose tissue using a slight modi®cation of Rodbell's collagenase method. They were incubated in the presence of various agents for 2 hrs at 37 C in Krebs-Ringer buffer (pH 7.4) at a concentration of 3 ± 5 Â 10 5 cellsaml. Leptin concentration in the extracellular medium was measured by radioimmunoassay. RESULTS: Dose-response curves revealed that insulin (0.1 nM ± 100 nM) increased basal rates of leptin secretion in a linear manner for at least 2 hrs. Insulin (100 nM) nearly doubled the basal rates of leptin secretion from International Journal of Obesity (2001) 25, Suppl 2, S25±S26 ß 2001 Nature Publishing Group All rights reserved 0307±0565/01 $15.00 www.nature.com/ijo International Journal of Obesity (2001) 25, Suppl 2, S25±S26 ß 2001 Nature Publishing Group All rights reserved 0307±0565/01 $15.00 www.nature.com/ijo 4.1 AE 0.2 to 7.9 AE 0.3 ng leptin . 10 76 cells . 2 hrs 71 (P`0.01). The adrenergic agonists noradrenaline (a general b agonist) (1 mM), isoproterenol (potent b1, b2 and weak b3) (0.1 mM) or CL 316,243 (potent b3) (10 nM) all inhibited insulin (10 nM)-stimulated leptin release. Propranolol (a potent b1-, b2-and weak b3-adrenergic antagonist) (10 mM) entirely reversed the inhibitory effects of noradrenaline or isoproterenol but it only partially reversed the inhibitory action of CL 316,243. The inhibitory effects of noradrenaline and isoproterenol on insulin-stimulation of leptin secretion could also completely be reversed by the selective b1-antagonist ICI 89406. The selective b2-antagonist ICI 118551 was much less effective in reversing the action of noradrenaline or isoproterenol. Insulin-stimulated leptin secretion could also be inhibited by a wide variety of agents increasing intracellular cAMP levels such as lipolytic hormones (ACTH, TSH), cAMP analogues, pertussis toxin, forskoline, methylxanthines (cafeine, theophylline, IBMX) and speci®c inhibitors of phosphodiesterase III (imazodan, milrinone and amrinone). CONCLUSIONS: It is concluded that the effects of noradrenaline and other badrenergic agonists are mainly mediated via b1-and b3-adrenergic pathways, b2-receptors playing a minor role. Moreover, it is suggested that: (1) activation of phosphodiesterase Ill by insulin represents an important metabolic step in stimulation of leptin secretion, and (2) 
The apM1 (Adipose Most abundant gene transcript) gene encodes a secretory protein, adiponectin (ApN) that may exert anti-atherogenic properties. Circulating ApN levels are decreased in obese subjects or in patients with cardiovascular disease, and apM1 mRNA levels are also reduced in adipose tissue from obese subjects. Regulation of ApN and ApM1 has only been scarcely explored. In this study, we investigated the hormonal regulation of apM1 gene in cultured human adipose tissue. METHODS: Visceral adipose tissue was obtained from 31 subjects (age, 46 AE 2 yr; BMI, 31 AE 2 kgam 2 ) undergoing elective abdominal surgery, and tissue explants (isolated adipocytes in a few cases) were cultured in MEM for up to 32 h. RESULTS: Adiponectin was detected by Western-blot in medium from isolated adipocytes, and apM1 gene was highly expressed in the adipocyte fraction, but not in the stromal-vascular fraction, from adipose tissue. ApM1 gene expression decreased spontaneously when adipose explants were cultured in basal medium for 24 h, while the expression of other adipose genes (PAI-1, GAPDH) even increased. The fall of apMI mRNA was prevented by the addition of actinomycin D, an inhibitor of transcription, or by cycloheximide, an inhibitor of protein synthesis. This fall was also partially prevented when the amount of adipose tissue per volume of culture medium was reduced. This suggests that a newly synthesised factor released by adipose tissue destabilises apM1 mRNA. The hormonal regulation of apMl gene was next examined. Dexamethasone tended to accelerate the decrease of apMl mRNA levels, while cAMP (the second messenger of catecholamines) markedly reduced (by 70%) apM1 gene expression. Lastly, both insulin and IGFI induced a signi®cant rise in apM1 mRNA ($170% of controls). CONCLUSIONS: The expression of apM1 is negatively regulated by glucocorticoids and cAMP and positively by insulin and IGF1 in human adipose tissue. This regulation could contribute to the variations of ApN levels in the plasma and explain the paradoxical decrease of an adipose-speci®c protein in insulin-resistant patients with obesity andaor the Metabolic Syndrome and the subsequent risk for cardiovascular disease. Adipose tissue may also regulate its own secretion of ApN by releasing a factor that destabilises apM1 mRNA.
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Ghrelin and obesity in humans Ghrelin is a potent GH secretagogue in rodents and humans. In rodents, chronic administration of ghrelin causes weight gain by increasing food intake and reducing fat utilization. METHODS: To investigate the possible involvement of ghrelin in the pathogenesis of human obesity, we measured body composition (DEXA) and fasting and post-prandial plasma ghrelin concentrations (RIA) in 15 Caucasian (8Ma7F, 31 AE 9 y, 92AE 24 kg, 29 AE 10% body fat, mean AE SD) and 15 Pima Indians (8Ma7F, 33 AE 5 y, 97AE 29 kg, 30 AE 8% body fat). RESULTS: In the whole group, fasting plasma ghrelin concentration was negatively correlated with percent body fat (r 70.45; p 0.01), fasting plasma insulin concentration (r 0.45; p 0.01) and fasting plasma leptin concentration (r 70.38; p 0.03). In a stepwise regression analysis, insulin was the only signi®cant variable in the model, explaining 34% of the variance in plasma ghrelin concentration. When groups were compared, Pima Indians (a population with a very high prevalence of obesity) had lower ghrelin concentrations than Caucasians (87 AE 28 vs 129 AE 34 fmolaml; p `0.01), even after adjustment for fasting plasma insulin concentration. In the whole group or in each of the groups, plasma ghrelin concentration did not change after a standardized meal (20% of daily energy requirements, 40% CHO, 44% fat, 16% prot). CONCLUSIONS: Plasma ghrelin concentration is decreased in human obesity. While these ®ndings do not seem to support the adipogenic properties of ghrelin observed in rodents, prospective clinical studies are now needed to establish the potential role of ghrelin in the pathogenesis of human obesity.
